Neon's cancer vaccine makes a decent early showing, but overall survival remain a crucial measure.
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
Sangamo is slowly building a case for SB-525 over Biomarin’s valrox.
Turning Point is heading into a highly competitive lung cancer niche with its lead project, which still has much to prove.
Orencia’s late-stage failure in Sjögren’s has dashed hopes of a therapy soon, but the mid-stage pipeline is crowded, with Novartis, Glaxosmithkline and Galapagos all…
Protagonist Therapeutics and Pfizer will soon get an idea of their respective chances in beta-thalassaemia and Duchenne muscular dystrophy.
Mirati Therapeutics nearly stole the show at Asco despite not actually presenting – a fact that illustrates how low on meaningful data this year's conference was.
Amgen has gone further than anyone before to crack KRAS, but caution is required, as efficacy might ultimately not be as positive as initial data suggest.
First-look data on Abbott’s tricuspid-focused MitraClip follow-on device are promising, but can TriClip emulate its predecessor’s success?